We focus on translational research that will lead to novel therapeutics development for MYC-driven cancers, particularly for leukemia, neuroblastoma, and triple-negative breast cancer.  The research strategy of our laboratory is to leverage the genetic, imaging, and pharmacological capacities of the zebrafish models of cancer together with human cancer studies for the discovery of effective and specific targets and leads. We actively seek to partner with industry and clinicians to reach the long-term goal of our research: improved management and treatment of aggressive and metastatic cancers.